Abstract
Emicizumab is a recombinant, humanised bispecific anti-body which acts as a FVIII mimetic and is a therapeutic option for haemophilia A. Plasma emiciz......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
